leadf
logo-loader

Arecor

 Receive alerts
Market:
Unlisted (UK)
Market Cap:
-
Price
-
Change
-
52 weeks high
-
52 weeks low
-
08.16

Director Interviews

In brief

Arecor is ‘advancing today’s therapies to enable healthier lives’ by developing a broad portfolio of therapies for its proprietary pipeline and in partnership with leading pharmaceutical and biotech companies

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

Arecor advancing today’s therapies to enable healthier lives
Arecor -

Snapshot

  • Arecor uses its ground-breaking technology platform, Arestat™ to develop future medicines from existing therapies, across all disease indications and at any stage of a drug lifecycle
  • Proprietary portfolio includes first franchise in diabetes and has expanded its development pipeline into anti-infectives
  • Partners with leading pharmaceutical and biotech companies to improve their products, find solutions or create next-generation products
Open Deep dive

Latest news

Arecor licenses first formulation to partner Inhibrx

on 17/12/20

Arecor publishes promising clinical trial data for ultra-fast insulin candidate

on 16/12/20

Arecor doses first patient in ultra-concentrated insulin trial

on 14/12/20

Arecor and Hikma expand collaboration to second product

on 20/10/20

Arecor to present abstract of ultra-rapid acting insulin formulation at EASD...

on 21/9/20

Arecor says insulin formulation passes landmark with successful phase 1 study

on 15/6/20

Arecor extends collaboration deal with US biotech

on 19/3/20

Arecor achieves important second, contractual milestone with one of its...

on 25/2/20

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Arecor -
Arecor punches above its weight with trials for fast-acting diabetes drugs

Investors are placing bets on a small British biotech to rival big pharma as it pushes its first diabetes drug through clinical trials

on 14/11/19

Watch

Arecor - Arecor licenses first formulation to partner Inhibrx, taking their lung disease product to clinic Director Interviews Arecor licenses first formulation to partner Inhibrx, taking their lung disease product to clinic
on 17/12/20
Hikma Pharmaceuticals PLC - Hikma Pharmaceuticals and Arecor strike a second strategic partnership deal Big caps Hikma Pharmaceuticals and Arecor strike a second strategic partnership deal
on 20/10/20
Arecor - Arecor CEO updates as data for lead insulin product is presented at American Diabetes Association Director Interviews Arecor CEO updates as data for lead insulin product is presented at American Diabetes Association
on 15/6/20
Arecor - Arecor's Sarah Howell discusses results from successful phase I insulin trial Director Interviews Arecor's Sarah Howell discusses results from successful phase I insulin trial
on 17/12/19
View all